Press Releases from DelveInsight Business Research LLP (2368 total)
Lupus Nephritis Pipeline Analysis Covering Clinical Trials, Emerging Therapies, …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 20+ key pharma and biotech companies are working on 25+ pipeline drugs in the Lupus Nephritis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Lupus Nephritis Pipeline Insight" report by…
Cerebral Adrenoleukodystrophy (cALD) Market Forecasts by DelveInsight Signal Gro …
The Cerebral Adrenoleukodystrophy (cALD) Market is undergoing a significant transformation with advancements in gene therapy and stem cell transplantation offering promising treatment avenues. Research efforts are focused on developing targeted therapies to address the underlying genetic mutations responsible for cALD progression. Additionally, collaborations between academia, and pharmaceutical companies are driving awareness and accelerating the development of novel interventions, ushering in a new era of hope for patients and families affected…
Polycythemia Vera Market to Advance at Moderate CAGR During the Forecast Period …
The Polycythemia Vera market is witnessing a transformative evolution with the introduction of novel therapies targeting the underlying molecular mechanisms of the disease. Advancements in understanding the genetic and molecular pathways involved in Polycythemia Vera are driving the development of targeted treatments with the potential to improve disease management and patient outcomes. Furthermore, there's a growing emphasis on personalized medicine approaches, aiming to tailor treatments based on individual patient characteristics,…
Pancreatic Cancer Market to Register Stunning Growth During the Forecast Period …
The Pancreatic Cancer Market is experiencing a paradigm shift fueled by breakthroughs in targeted therapies, immunotherapies, and precision medicine approaches. Novel treatment options are emerging, offering hope for improved outcomes and quality of life for patients. Additionally, advancements in early detection methods and personalized treatment strategies are reshaping the landscape, driving toward more effective and tailored approaches to managing this challenging disease.
DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast…
EGFR Inhibitors-Induced Skin Disorders Market to Observe Stupendous Growth Durin …
The EGFR Inhibitors-Induced Skin Disorders Market is evolving rapidly with the introduction of innovative topical and systemic treatments aimed at managing dermatologic side effects. Pharmaceutical companies are focusing on developing targeted therapies to alleviate symptoms such as rash, itching, and dry skin caused by EGFR inhibitors. Furthermore, advancements in supportive care and skincare regimens are enhancing patient comfort and adherence to treatment, reflecting a growing commitment to addressing the dermatologic…
Non-Hodgkin's Lymphoma (NHL) Market to Register Sustainable Growth During the Fo …
The Non-Hodgkin's lymphoma market is undergoing significant evolution with the advent of novel targeted therapies and immunotherapies. These advancements are revolutionizing treatment options, offering improved efficacy and reduced side effects compared to traditional chemotherapy. Additionally, precision medicine approaches based on molecular profiling are enabling more personalized treatment strategies, contributing to a shift towards more tailored and effective care for patients with Non-Hodgkin's lymphoma.
DelveInsight's "Non-Hodgkin's Lymphoma (NHL) Market Insights, Epidemiology, and…
Obstructive Sleep Apnea (OSA) Market is Projected to Grow During the Forecast Pe …
The Obstructive Sleep Apnea market is witnessing a transformative shift, driven by technological advancements and a growing awareness of sleep disorders. Innovations in diagnostic devices and therapies, coupled with a rising emphasis on personalized medicine, are reshaping treatment approaches.
DelveInsight's "Obstructive Sleep Apnea (OSA) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Obstructive Sleep Apnea…
Metastatic Melanoma Pipeline, FDA Approvals, Clinical Trials Developments and Co …
DelveInsight's, "Metastatic Melanoma Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Melanoma pipeline landscape. It covers the Metastatic Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Metastatic…
Relapsed or Refractory Myelodysplastic Syndrome Pipeline, FDA Approvals, Clinica …
DelveInsight's, "Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the Relapsed or Refractory Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsed or Refractory Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights…
Spinal Cord Injury Pipeline, FDA Approvals, Clinical Trials Developments and Com …
DelveInsight's, "Spinal Cord Injury Pipeline Insight 2024" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in the Spinal Cord Injury pipeline landscape. It covers the Spinal Cord Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spinal Cord Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key…
Crohn's Disease Pipeline, FDA Approvals, Clinical Trials Developments and Compan …
DelveInsight's, "Crohn's Disease Pipeline Insight, 2024" report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn's Disease pipeline landscape. It covers the Crohn's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Crohn's Disease…
Ulcerative Colitis Pipeline, FDA Approvals, Clinical Trials Developments, and Co …
DelveInsight's, "Ulcerative Colitis Pipeline Insight 2023" report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in the Ulcerative Colitis pipeline landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Ulcerative…
Peanut Allergy Pipeline, FDA Approvals, Clinical Trials Developments, and Compan …
DelveInsight's, "Peanut Allergy Pipeline Insight, 2023," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Peanut Allergy pipeline landscape. It covers the Peanut Allergy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peanut Allergy Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Peanut…
Epilepsy Pipeline, FDA Approvals, Clinical Trials Developments and Companies 202 …
DelveInsight's, "Epilepsy Pipeline Insight, 2023" report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Epilepsy Pipeline Report
• DelveInsight's Epilepsy pipeline report…
Duchenne Muscular Dystrophy Pipeline, FDA Approvals, Clinical Trials Development …
DelveInsight's, "Duchenne Muscular Dystrophy Pipeline Insight 2023," report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including Duchenne Muscular Dystrophy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key…
Biliary Tract Cancers Pipeline, FDA Approvals, Clinical Trials Developments and …
DelveInsight's, "Biliary Tract Cancers Pipeline Insight, 2023," report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Biliary Tract Cancers pipeline landscape. It covers the Biliary Tract Cancers pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Biliary Tract Cancers pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key…
Wet Age-Related Macular Degeneration Pipeline 2024
DelveInsight's, "Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Insight, 2024," report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the Wet Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key…
PCSK9 Inhibitor Pipeline Insights Report 2024
(Albany, United States) As per DelveInsight's assessment, globally, the PCSK9 Inhibitor Pipeline constitutes 14+ key companies continuously working towards developing 14+ PCSK9 Inhibitor Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the PCSK9 Inhibitor Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, PCSK9 Inhibitor NDA approvals (if any),…
Hyperphosphatemia Pipeline Insight Report 2024
(Albany, United States) As per DelveInsight's assessment, globally, the Hyperphosphatemia Pipeline constitutes 15+ key companies continuously working towards developing 15+ Hyperphosphatemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Hyperphosphatemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hyperphosphatemia NDA approvals (if any), and product development activities comprising…
Hepatorenal Syndrome Pipeline Insights Report 2024
(Albany, United States) As per DelveInsight's assessment, globally, the Hepatorenal Syndrome Pipeline constitutes 3+ key companies continuously working towards developing 3+ Hepatorenal Syndrome Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Hepatorenal Syndrome Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Hepatorenal Syndrome NDA approvals (if…
Parkinson's Disease Psychosis Pipeline Insight Report 2024 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Parkinson's disease Psychosis Pipeline constitutes 5+ key companies continuously working towards developing 5+ Parkinson's Disease Psychosis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Parkinson's Disease Psychosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any),…
Oral Mucositis Pipeline Insight Reports 2024 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Oral Mucositis Pipeline constitutes 10+ key companies continuously working towards developing 10+ Oral Mucositis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Oral Mucositis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Oral Mucositis NDA approvals (if any), and…
QSYMIA (Phentermine- topiramate) Market Size and Share Analysis Across 7MM and C …
DelveInsight has released a comprehensive report titled "QSYMIA (Phentermine- topiramate) Market Forecast" offering a thorough examination and predictive insights into the QSYMIA (Phentermine- topiramate) market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of QSYMIA (Phentermine- topiramate) in the therapeutics landscape…
IMCIVREE (Setmelanotide) Market Size and Share Analysis Across 7MM and Competiti …
DelveInsight has released a comprehensive report titled "IMCIVREE (Setmelanotide) Market Forecast" offering a thorough examination and predictive insights into the IMCIVREE (Setmelanotide) market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of IMCIVREE (Setmelanotide) in the therapeutics landscape for Obesity across…
Sapablursen Market Size and Share Across 7MM and Competitive Landscape by DelveI …
DelveInsight has released a comprehensive report titled "Sapablursen Market Forecast" offering a thorough examination and predictive insights into the Sapablursen market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of Sapablursen in the therapeutics landscape for Polycythemia Vera across the 7MM,…
Sapablursen Market Size and Share Analysis Across 7MM and Competitive Landscape …
DelveInsight has released a comprehensive report titled "Sapablursen Market Forecast" offering a thorough examination and predictive insights into the Sapablursen market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of Sapablursen in the therapeutics landscape for Polycythemia Vera across the 7MM,…
Complicated Urinary Tract Infections (cUTIs) Market Poised for Extraordinary Gro …
The Complicated Urinary Tract Infections (cUTIs) market is dynamically evolving with the development of novel antimicrobial agents, increased focus on antibiotic stewardship, and advancements in diagnostic technologies, offering the potential for more targeted and effective treatment options. Growing awareness of antibiotic resistance and the demand for alternative therapies are driving innovation and shaping the landscape of cUTI management, fostering improved patient outcomes.
DelveInsight's "Complicated Urinary Tract Infections (cUTIs) Market Insights, Epidemiology,…
Multiple Sclerosis Market Forecasts by DelveInsight Signal Groundbreaking Growth …
The Multiple Sclerosis (MS) market is experiencing significant evolution with the introduction of innovative disease-modifying therapies, advancements in precision medicine approaches, and increasing emphasis on personalized treatment strategies, promising improved management and outcomes for patients. Ongoing research efforts and the expanding understanding of the underlying mechanisms of Multiple Sclerosis are driving innovation and shaping the landscape, ushering in a new era of care for individuals affected by this complex neurological…
Acute Respiratory Distress Syndrome (ARDS) Market Anticipating Remarkable Growth …
The Acute Respiratory Distress Syndrome (ARDS) market is undergoing notable evolution driven by advancements in critical care management, innovative therapeutic strategies, and improved understanding of the underlying pathophysiology, promising enhanced outcomes for affected patients. Ongoing research endeavors and growing emphasis on early detection and intervention are reshaping the landscape, ushering in new possibilities for the treatment and management of this complex condition.
DelveInsight's "Acute Respiratory Distress Syndrome (ARDS) Market Insights, Epidemiology,…
Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Expand at a Significant Gro …
The Non-Muscle Invasive Bladder Cancer (NMIBC) market is witnessing significant evolution with the introduction of novel therapies and advancements in diagnostic techniques, paving the way for more personalized treatment approaches and improved patient outcomes. Rapid research developments and increasing awareness are reshaping the landscape, offering new avenues for effective management of this condition.
DelveInsight's "Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding…
Graft Versus Host Disease (GvHD) Market Set to Experience Unprecedented Growth D …
The Graft Versus Host Disease (GvHD) market is dynamically evolving with advancements in targeted therapies and improved understanding of immune modulation, offering new hope for patients grappling with this complex condition. Emerging treatments and personalized approaches signify promising prospects for more effective management and enhanced patient outcomes in the future.
DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease,…
Donohue syndrome Market to Witness Growth, asserts DelveInsight | Major players …
DelveInsight's "Donohue syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Donohue syndrome, historical and forecasted epidemiology, as well as the Donohue syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Donohue syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Donohue syndrome market size…
Diamond-Blackfan anemia (DBA)/Aase Syndrome Market to Witness Growth, asserts De …
DelveInsight's "Diamond-Blackfan anemia (DBA) / Aase Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Diamond-Blackfan anemia (DBA) / Aase Syndrome, historical and forecasted epidemiology as well as the Diamond-Blackfan anemia (DBA) / Aase Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Diamond-Blackfan anemia (DBA) / Aase Syndrome market report provides current treatment practices, emerging drugs,…
Esophageal Squamous Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Deve …
DelveInsight's, "Esophageal Squamous Cell Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the Esophageal Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key…
Mesothelioma Pipeline, FDA Approvals, Clinical Trials Development and Companies …
DelveInsight's, "Mesothelioma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Mesothelioma pipeline landscape. It covers the Mesothelioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mesothelioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Mesothelioma Pipeline Report
• DelveInsight's Mesothelioma…
Marginal Zone Lymphoma Pipeline, FDA Approvals, Clinical Trials Development and …
DelveInsight's, "Marginal Zone Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key…
HR Positive/ HER2 Negative Breast Cancer Pipeline Outlook Report 2024
DelveInsight's, "HR Positive/ HER2 Negative Breast Cancer Pipeline Insights 2024" report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape. It covers the HR Positive/ HER2 Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HR Positive/ HER2 Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule…
EGFR Non-Small Cell Lung Cancer Pipeline Report 2024
DelveInsight's, "EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insights 2024" report provides comprehensive insights about 40+ EGFR Non-Small Cell Lung Cancer companies and 42+ pipeline drugs in the EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage,…
Follicular Lymphoma Pipeline Insights Report 2024
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Urothelial Carcinoma Pipeline Insights Report 2024
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Recurrent Glioblastoma Pipeline, FDA Approvals, Clinical Trials Developments and …
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Recurrent Glioblastoma companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the Recurrent Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from…
BESREMi (ropeginterferon alfa-2B) Market Size and Share Analysis Across 7MM and …
DelveInsight has released a comprehensive report titled "BESREMi Market Forecast" offering a thorough examination and predictive insights into the BESREMi market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of BESREMi in the therapeutics landscape for Polycythemia Vera across the 7MM…
Rusfertide Market Size and Share Across 7MM and Competitive Landscape by DelveIn …
DelveInsight has released a comprehensive report titled "Rusfertide Market Forecast" offering a thorough examination and predictive insights into the Rusfertide market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of Rusfertide in the therapeutics landscape for Polycythemia Vera across the 7MM,…
JAKAFI Market Size and Share Analysis Across 7MM and Competitive Landscape by De …
DelveInsight has released a comprehensive report titled "JAKAFI Market Forecast" offering a thorough examination and predictive insights into the JAKAFI market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of JAKAFI in the therapeutics landscape for Bronchiolitis Obliterans Syndrome across the…
Interleukin-18 (IL-18) Inhibitor Pipeline Assessment Covering Clinical Trials, E …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 4+ key pharma and biotech companies are working on 4+ pipeline drugs in the Interleukin-18 (IL-18) Inhibitor therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Interleukin-18 (IL-18) Inhibitor Pipeline Insight"…
Interleukin-2 (IL-2) Inhibitor Pipeline Assessment Covering Clinical Trials, Eme …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 10+ pipeline drugs in the Interleukin-2 (IL-2) Inhibitor therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Interleukin-2 (IL-2) Inhibitor Pipeline Insight"…
Factor IX Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 5+ key pharma and biotech companies are working on 5+ pipeline drugs in the Factor IX therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Factor IX Pipeline Insight" report by…
H3N2 infection Pipeline Assessment Covering Clinical Trials, Emerging Therapies, …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 20+ pipeline drugs in the H3N2 infection therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"H3N2 infection Pipeline Insight" report by…
Vasculitis Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 30+ pipeline drugs in the Vasculitis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Vasculitis Pipeline Insight" report by DelveInsight provides…
Pancreatic Cancer Competitive Landscape Report 2023 (Updated)
DelveInsight's, "Pancreatic Cancer Competitive landscape 2023" report provides comprehensive insights about 250+ Pancreatic Cancer Companies and 300+ drugs in Pancreatic Cancer Competitive landscape. It covers the Pancreatic Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Pancreatic Cancer Competitive Landscape Report
• DelveInsight's Pancreatic Cancer report depicts a robust space with 250+ Pancreatic Cancer…
